SAN DIEGO, March 24 /PRNewswire-FirstCall/ -- Nanogen, Inc.
(Nasdaq: NGEN), developer of advanced diagnostic products, announced today
that it was issued U.S. Patent No. 6,867,048, "Multiplexed Active Biologic
Array" by the U.S. Patent and Trademark Office. The '048 patent relates to a
method of addressing one or more electrodes (or "test sites") across multiple
rows and columns of a microarray. The patent also covers a method for storing
the value of the voltage associated with each electrode in a local memory.
This "smart chip" technology is a key feature of Nanogen's NanoChip(R)
400 electronic microarray, the company's second generation multi-purpose
system for developing and performing molecular diagnostic tests.
Using local memory circuits provides for precise control of the currents
delivered to individual electrodes on the array, while minimizing the
utilization of "off-chip" circuitry and overall system costs. The electric
potential is controlled at each of the NanoChip's 400 test sites to move and
concentrate DNA or RNA, providing accuracy, speed and flexibility for
developing molecular diagnostic tests. Storing critical voltage information
allows for precise control of the biological molecules during analysis and
increases data management efficiency by tracking test site activation and
array usage directly on the electronic microarray cartridge.
"This addition to our growing intellectual property portfolio illustrates
our ability to develop differentiated advanced diagnostic products that add
value to the company and to research and clinical laboratory customers," said
Howard C. Birndorf, Nanogen chairman of the board and CEO.
This new patent expands Nanogen's intellectual property portfolio to
include 114 patents issued in the U.S.
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
and broad suite of analyte specific reagents to develop tests to detect
infectious diseases, drug toxicity and mutations associated with cancer,
cardiovascular and genetic diseases. The next generation instrument system,
the NanoChip(R) 400, is expected to be available in 2005. Nanogen's
subsidiary SynX offers a line of point-of-care diagnostic tests and is
building expertise in cardiac related health conditions. Nanogen's ten years
of pioneering research involving nanotechnology may also have future
applications in medical diagnostics, biowarfare and other industries. For
additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.